The third-place slot marked another return to form. Novo Nordisk’s Wegovy reclaimed the seat it held in December, backed by ...

AbbVie (NYSE:ABBV) recently announced the availability of its drug SKYRIZI® in Canada for treating adults with ulcerative ...

Skyrizi (risankizumab-rzaa) is prescribed for Crohn’s disease and certain other inflammatory conditions. As with other drugs, Skyrizi can cause side effects, such as headache and injection site ...

The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research ...

Merck’s Keytruda holds on to the top spot while AbbVie’s Humira—once the world’s top-selling drug—continues to cede its ...

(RTTNews) - AbbVie Inc. (ABBV) Tuesday said that its Skyrizi approved for the treatment of adults with moderately to severely active ulcerative colitis is now available in Canada. Ulcerative ...

Gov. Wes Moore made lowering drug costs a key campaign promise, making advocates of the law confident that their greatest ...

The top 10 projected best-selling medications in 2026, including GLP-1 drugs and AbbVie's Skyrizi, have expected global sales reaching up to $31 billiion.

AbbVie's strategic move into the obesity market through a partnership with Gubra A/S shows potential but won't impact revenue ...

I often say that investing rarely has a dull moment, which is why I find it so fascinating. The beginning of 2025 certainly ...